AC Immune Dirección

Dirección controles de criterios 4/4

El CEO de AC Immune's es Andrea Pfeifer , nombrado en Apr 2003, tiene una permanencia de 7.92 años. compensación anual total es CHF1.57M, compuesta por 35.6% salario y 64.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.58% de las acciones de la empresa, por valor de $5.54M. La antigüedad media del equipo directivo y de la junta directiva es de 5.2 años y 6 años, respectivamente.

Información clave

Andrea Pfeifer

Chief Executive Officer (CEO)

CHF1.6m

Compensación total

Porcentaje del salario del CEO	35.6%
Permanencia del CEO	21yrs
Participación del CEO	2.6%
Permanencia media de la dirección	5.2yrs
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrea Pfeifer en comparación con los beneficios de AC Immune?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CHF54m
Sep 30 2023	n/a	n/a	-CHF68m
Jun 30 2023	n/a	n/a	-CHF67m
Mar 31 2023	n/a	n/a	-CHF69m
Dec 31 2022	CHF2m	CHF558k	-CHF71m
Sep 30 2022	n/a	n/a	-CHF73m
Jun 30 2022	n/a	n/a	-CHF76m
Mar 31 2022	n/a	n/a	-CHF75m
Dec 31 2021	CHF2m	CHF530k	-CHF73m
Sep 30 2021	n/a	n/a	-CHF71m
Jun 30 2021	n/a	n/a	-CHF74m
Mar 31 2021	n/a	n/a	-CHF71m
Dec 31 2020	CHF2m	CHF520k	-CHF62m
Sep 30 2020	n/a	n/a	-CHF62m
Jun 30 2020	n/a	n/a	-CHF25m
Mar 31 2020	n/a	n/a	-CHF26m
Dec 31 2019	CHF2m	CHF510k	CHF45m
Sep 30 2019	n/a	n/a	CHF50m
Jun 30 2019	n/a	n/a	CHF18m
Mar 31 2019	n/a	n/a	CHF24m
Dec 31 2018	CHF2m	CHF455k	-CHF51m
Sep 30 2018	n/a	n/a	-CHF32m
Jun 30 2018	n/a	n/a	-CHF27m
Mar 31 2018	n/a	n/a	-CHF29m
Dec 31 2017	CHF2m	CHF404k	-CHF26m

Compensación vs. Mercado: La compensación total ($USD1.72M) de Andrea está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD1.60M).

Compensación vs. Ingresos: La compensación de Andrea ha sido consistente con los resultados de la empresa en el último año.

CEO

Andrea Pfeifer (66 yo)

21yrs

Permanencia

CHF1,568,000

Compensación

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrea Pfeifer	Co-Founder	21yrs	CHF1.57m	2.58% CHF 5.7m
Christopher Roberts	CFO & VP of Finance	2yrs	sin datos	0.013% CHF 29.6k
Piergiorgio Donati	Chief Technical Operations Officer	5.2yrs	sin datos	0.026% CHF 57.6k
Jean-Fabien Monin	Chief Administrative Officer	8.8yrs	sin datos	0.33% CHF 733.1k
Howard Donovan	Chief HR Officer	2yrs	sin datos	0.021% CHF 47.3k
Madiha Derouazi	Chief Scientific Officer	less than a year	sin datos	0.0034% CHF 7.5k
Gary Waanders	Senior VP of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Alexandre Caratsch	General Counsel	no data	sin datos	sin datos
Julian Snow	VP of U.S. Finance & Corporate Development	2yrs	sin datos	sin datos
David Hickman	Head of AD - SME	14.3yrs	sin datos	sin datos
Joseph Wettstein	Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer	8.2yrs	sin datos	sin datos
Oliver Sol	VP & Head of Clinical Development	no data	sin datos	sin datos

5.2yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ACIU es experimentado (5.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrea Pfeifer	Co-Founder	7.9yrs	CHF1.57m	2.58% CHF 5.7m
Jean-Marie Lehn	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Claude Nicolau	Member of Scientific Advisory Board	no data	sin datos	sin datos
Douglas Williams	Independent Non-Executive Chairman	6yrs	CHF194.00k	0.041% CHF 91.5k
Alf E. Lindberg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Detlev Riesner	Member of Scientific Advisory Board	no data	CHF5.00k	sin datos
Fred Van Leuven	Member of Scientific Advisory Board	no data	CHF105.00k	sin datos
I. Rosenberg	Member of Scientific Advisory Board	no data	sin datos	sin datos
M. Monsigny	Member of Scientific Advisory Board	no data	sin datos	sin datos
E. Lestringant	Member of Scientific Advisory Board	no data	sin datos	sin datos
Monika Butler	Independent Vice Chair	2.5yrs	CHF208.00k	0.0097% CHF 21.5k
Andreas Monsch	Head of Clinical Advisory Board	no data	sin datos	sin datos

6.0yrs

Permanencia media

73.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ACIU se considera experimentada (6 años de antigüedad promedio).

AC Immune Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Co-Founder notifies of intention to sell stock

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Recent updates

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Consensus forecasts updated

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

AC Immune SA, Annual General Meeting, Mar 31, 2021

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

New 90-day high: US$8.43

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: US$6.53

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

New 90-day high: US$5.68

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

AC Immune Sa Appoints Carl H. June as Board of Directors